Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir.
Conclusions: In patients with treatment-naïve CHB and good adherence to ETV treatment in the real world, LLV during treatment is not a predictive factor for HCC and cirrhotic complications. It may be unnecessary to adjust their antiviral agent for patients with good adherence who experience LLV during ETV treatment.
PMID: 32466635 [PubMed - as supplied by publisher]
Source: Clinical and molecular hepatology - Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research
More News: Cancer & Oncology | Carcinoma | Gastroenterology | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Transplant | Study | Transplants | Urology & Nephrology | Virology